Results 41 to 50 of about 1,267,326 (360)

Business Advisory in Private Equity

open access: yesSymphonya, 2007
The extraordinary growth of Private Equity over the use last ten years has led to this capital market sector becoming a fully-fledged industry with specific operational skills, methodologies and capabilities. Private Equity is constantly seeking out new
Emanuele Cairo
doaj   +1 more source

A supplier development service for the East Midlands feasibility study [PDF]

open access: yes, 2009
This study assesses the need for a Supplier Development Service (SDS) in the East Midlands. Research was undertaken into previous and current programmes of this type and sets out a proposed model for the ...
Business to Business, Larch Consulting
core  

Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Secondary hyperparathyroidism (SHPT) is a common complication in patients receiving maintenance dialysis, driven by calcium and phosphate metabolism disturbances. Calcimimetics are central to the management of SHPT by enhancing calcium‐sensing receptor sensitivity and reducing parathyroid hormone secretion.
Fumihiko Koiwa   +3 more
wiley   +1 more source

Web-based Consulting Company Employee Timesheet [PDF]

open access: diamond, 2023
Gabriella Clara Pertiwi   +2 more
openalex   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

open access: yesMolecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son   +13 more
wiley   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

A supplier development service for the East Midlands feasability study [PDF]

open access: yes, 2009
This study assesses the need for a Supplier Development Service (SDS) in the East Midlands. Research was undertaken into previous and current programmes of this type and sets out a proposed model for the ...
Business to Business, Larch Consulting
core  

Designing a consulting services architecture model [PDF]

open access: yes, 2015
textDuring my years of experience in the technology industry, it has become obvious that standard processes and methodologies within the engineering discipline are at a mature state.
Pinkston, Jeffrey Lynn
core   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

open access: yesMolecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy